{"ticker": {"uuid": "53c26305-b507-431f-b6fd-4b23c2f1dde1", "symbol": "RNTX", "name": "Rein Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Rein Therapeutics (RNTX) Slips 1.78% as Stock Nears Key Support Level - McClellan Summation", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOa2ctSUk3aU02Mk9Zd0VrV1Fnc3E0WG9TV1dMV3lESS1ZV21uOHRteFdidUxEb0paR25GeHhHOG9ocDdFR09hdWFScUp5Tkc1NUszX29Xem5CQ2hZU0k0ejFpejBQY1l6eXhRd0lNY0ttR3J1YnY4alpoOHNIQWVFQWJFUFNnQlhtOWpySzlUTWJUMks4M3A4NVBKN3k4d3JvVk9QZzlTaW1TWVBvYUNqcE5rUkwyQQ?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-07-11T17:36:04+00:00", "published_display": "11 Jul 2026 17:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Rein Therapeutics, Inc. \u2013 NASDAQ:RNTX", "summary": "The article provides a title indicating \"Price to sales forward of Rein Therapeutics, Inc. \u2013 NASDAQ:RNTX\" and appears to be a financial data page from TradingView. It lists the company, its Nasdaq stock market ticker, and general financial and market information categories. Howev", "url": "https://www.tradingview.com/symbols/NASDAQ-RNTX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T15:40:22", "published_display": "10 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Rein Therapeutics, Inc. \u2013 NASDAQ:RNTX", "summary": "This article focuses on the enterprise value to revenue forward metric for Rein Therapeutics, Inc. (NASDAQ: RNTX). It appears to be a financial data point presented within a larger financial platform context, offering a snapshot of a specific valuation ratio for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-RNTX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T02:10:48", "published_display": "08 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Rein Therapeutics, Inc. \u2013 BOATS:RNTX", "summary": "The article discusses the \"Price to sales forward\" metric for Rein Therapeutics, Inc. (RNTX) on the Blue Ocean Alternative Trade System (BOATS) platform. This financial data is provided by TradingView, indicating that the market for RNTX was closed with no trades recorded at the ", "url": "https://www.tradingview.com/symbols/BOATS-RNTX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T20:11:11", "published_display": "07 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Rein Therapeutics, Inc. \u2013 BOATS:RNTX", "summary": "The article focuses on the \"Price to earnings forward\" metric for Rein Therapeutics, Inc. (RNTX), listed on the Blue Ocean Alternative Trade System (BOATS). It presents a financial data point for the pharmaceutical company but does not offer any specific figures or analysis withi", "url": "https://www.tradingview.com/symbols/BOATS-RNTX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T13:10:40", "published_display": "07 Jul 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Inc. (RNTX) Q1 2026 Earnings: Narrowed Loss Beats Estimates as Cash Management Improves", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxNUkI2U2NlajRKNlVvRDVVR09kVG52LUM3V3RwWTNHTmlnODZUQ09UeEhIYkpXa2ptQ0VZMGVZZkwyOWMzZ0NJaDhSM1ZvN2hIS0RfR09xZ3dfVm1zMXJaZ2lWS2xtZlVFaG8tNnRkLUxVa2psX3h1UDNjR0RQU2RmTnNUWUFwaXRIcm1YejB5a0c5ZmRlQ0ZJZ0VtUWxXaklLaEo4d0pyRnlXV0pIYlNFNlAydTF5cDJKakVBQlNUSmo1UXV1NTBBVXVDaHNsc0NkMFIzTDc0SlVWMUZG?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-06T23:40:08+00:00", "published_display": "06 Jul 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RNTX - Rein Therapeutics Inc Latest SEC Filings", "summary": "This article provides the latest SEC filing information for Rein Therapeutics Inc. (RNTX), detailing its financial performance, key metrics like market capitalization and sales, and stock performance data. It includes various financial ratios, insider and institutional ownership ", "url": "https://finviz.com/stock?t=RNTX&ta=1&p=w&ty=lf&page=3", "source_name": "Finviz", "published_at": "2026-07-05T07:40:51", "published_display": "05 Jul 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Inc.(NasdaqCM:RNTX) added to Russell Microcap Value Benchmark Index", "summary": "Rein Therapeutics Inc. (NasdaqCM:RNTX) has been added to the Russell Microcap Value Benchmark Index. The biotechnology company, specializing in orphan pulmonary and fibrosis indications, saw its stock increase by 1.94%, with its share price trading at $0.9900. This news follows s", "url": "https://www.marketscreener.com/news/rein-therapeutics-inc-nasdaqcm-rntx-added-to-russell-microcap-value-benchmark-index-ce7f5fdfd989f325", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T13:40:08", "published_display": "29 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RNTX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Rein Therapeutics, Inc. (RNTX) stock for 2027, based on analyst opinions. It highlights a maximum and minimum price target of $8.00 and includes financial data, recent stock performance, and answers frequently asked questions ", "url": "https://www.tradingview.com/symbols/NASDAQ-RNTX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T15:09:36", "published_display": "25 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics, Inc Actuals & Estimates (NASDAQ:RNTX)", "summary": "This article provides an overview of Rein Therapeutics, Inc. (NASDAQ: RNTX) stock, including its current price, performance, and analyst forecasts. It details financial actuals and estimates, market capitalization, earnings per share, revenue, and other key financial data. The ar", "url": "https://www.tradingview.com/symbols/NASDAQ-RNTX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T15:09:36", "published_display": "25 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics (RNTX) Surges 5.87% as Stock Tests Key Resistance at $0.97 - Sweep Order Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQLVVCRjh3QnhtQUkwTW1MNmViZW5sNVJzMWdfaUVIOUJ6MW55TF82cl9rU3Fvd1RxeUhFc2lMdWtxVXROUjlJX0haekpKaUtOWjFtMEtGdUo3bzRNNjBnamJWSE5VMHllWjBYaThIQmIxemRTVXdHTXdJWHZHeE9OZnhzd2wwcUhtc1ZaeTJKUVZzUzBXYTA3ZS1JaTBSb1l5c3NmQUVNZmoxbkk4OEJidzMxRkRORHE0Rkc0?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-20T07:00:00+00:00", "published_display": "20 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Inc (RNTX) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Rein Therapeutics Inc (RNTX), highlighting its current valuation score and P/E ratio. The company's valuation score is 8.52, ranking it 118 out of 389 in the Biotechnology & Medical Research industry, with a P/E ratio of -0.48. Key va", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rntx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T13:11:14", "published_display": "19 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Inc (RNTX) Institutional Confidence", "summary": "Rein Therapeutics Inc's institutional shareholding score is 3.00, placing it at 193 out of 389 in the Biotechnology & Medical Research industry. The company's latest institutional shareholding proportion is 16.21%, a decrease of 51.20% quarter-over-quarter. James Simons is identi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rntx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-19T13:11:14", "published_display": "19 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Inc (RNTX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "The article provides an analysis of Rein Therapeutics Inc.'s (RNTX) financial health, noting its weak financial status and low operating efficiency with a score of 5.52, ranking 350 out of 389 in its industry. Key financial metrics such as cash and cash equivalents, total assets,", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rntx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-19T13:11:14", "published_display": "19 Jun 2026 13:11", "sentiment": "negative", "sentiment_pct": 31, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Inc (RNTX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Rein Therapeutics Inc (RNTX) currently holds an earnings forecast score of 7.00, placing it 316th out of 389 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $8.00 for RNTX, with a high of $10.00 and a low of $6.00, suggesting an upsi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rntx/earnings", "source_name": "TradingKey", "published_at": "2026-06-19T00:10:27", "published_display": "19 Jun 2026 00:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Inc (RNTX) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Rein Therapeutics Inc. (RNTX), highlighting that no specific risk assessment score is available for the company. It details various risk metrics such as volatility, maximum drawdown, and liquidity, and notes the company's beta value of ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rntx/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-18T19:09:49", "published_display": "18 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Inc (RNTX) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Rein Therapeutics Inc (RNTX), highlighting its major shareholders and institutional holdings. Voss Capital LLC is the largest reported shareholder, with significant institutional investment activity tracked over several quarters. ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rntx/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T16:39:09", "published_display": "17 Jun 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Inc (RNTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Rein Therapeutics Inc (RNTX), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. As of June 18, 2026, RNTX's price momentum score is 6.70, with the stock trading betwee", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rntx/technical", "source_name": "TradingKey", "published_at": "2026-06-17T12:09:50", "published_display": "17 Jun 2026 12:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "All You Need to Know About Rein Therapeutics Inc. (RNTX) Rating Upgrade to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPMkhYYUpmRVZfUjFmWmZld3hTTEJNQlZTSnJTa19XbVZqTWNycTllOHVzRTlodXFSVXU5R19KVUFWVTFlYVBZUXNBXzFQZDVxYTNCcW1oNV9aV2tBVFlNbDdJa2lGcVRyZFUxOGRmbTl1X1hrN25ndU9RSFdNVDl1OEdLeXl3MGxmUHRFT2lnQzZVNW9GXzlhN0FpeUI?oc=5", "source_name": "Market source", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Inc (RNTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for Rein Therapeutics Inc (RNTX). It notes that relevant data regarding business segments, regional revenue, and profit contribution for various fiscal years have not yet been disclosed by the company. The only specific in", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rntx/revenue", "source_name": "TradingKey", "published_at": "2026-06-16T17:09:47", "published_display": "16 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics enrolls 16 patients in lung fibrosis trial By Investing.com", "summary": "Rein Therapeutics announced that its Phase 2 RENEW clinical trial for LTI-03, targeting idiopathic pulmonary fibrosis, has enrolled 16 patients and randomized the first participant in the UK. The trial, which will evaluate the safety, tolerability, and efficacy of LTI-03, plans t", "url": "https://ng.investing.com/news/stock-market-news/rein-therapeutics-enrolls-16-patients-in-lung-fibrosis-trial-93CH-2553861", "source_name": "Investing.com Nigeria", "published_at": "2026-06-16T07:09:31", "published_display": "16 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom", "summary": "Rein Therapeutics announced the expansion of its Phase 2 RENEW clinical trial for LTI-03, an idiopathic pulmonary fibrosis treatment, into the United Kingdom, where the first patient has been randomized. The company has enrolled 16 patients to date, with clinical trial sites acti", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rein-therapeutics-expands-phase-2-120000289.html", "source_name": "Market source", "published_at": "2026-06-12T11:11:02", "published_display": "12 Jun 2026 11:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics enrolls 16 patients in lung fibrosis trial", "summary": "Rein Therapeutics has announced that its Phase 2 RENEW clinical trial for LTI-03, targeting idiopathic pulmonary fibrosis, has enrolled 16 patients to date, with the first patient randomized in the UK. The trial expects to enroll about 120 patients across multiple countries to ev", "url": "https://www.investing.com/news/company-news/rein-therapeutics-enrolls-16-patients-in-lung-fibrosis-trial-93CH-4737322", "source_name": "Investing.com", "published_at": "2026-06-11T12:09:28", "published_display": "11 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IPF trial for LTI-03 adds first UK patient, expands to 3 countries", "summary": "Rein Therapeutics (NASDAQ: RNTX) announced that the first patient has been randomized in the United Kingdom for its Phase 2 RENEW clinical trial evaluating LTI-03 for idiopathic pulmonary fibrosis (IPF), bringing the total enrollment to 16 patients across the US, Australia, and t", "url": "https://www.stocktitan.net/news/RNTX/rein-therapeutics-expands-phase-2-renew-trial-into-united-8c9pe1fismfm.html", "source_name": "Stock Titan", "published_at": "2026-06-11T12:09:28", "published_display": "11 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics (NASDAQ: RNTX) 2026 proxy outlines share boost, director elections, pay", "summary": "Rein Therapeutics' 2026 proxy statement details key items for its virtual annual meeting on July 20, 2026, including the election of two Class III directors, a proposal to double authorized common shares from 100 million to 200 million, and the ratification of CBIZ CPAs P.C. as t", "url": "https://www.stocktitan.net/sec-filings/RNTX/def-14a-rein-therapeutics-inc-definitive-proxy-statement-f39226f80277.html", "source_name": "Stock Titan", "published_at": "2026-06-09T08:40:55", "published_display": "09 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Rein Therapeutics(RNTX.US) With Buy Rating, Cuts Target Price to $8", "summary": "H.C. Wainwright has reiterated its Buy rating for Rein Therapeutics (RNTX.US) but has lowered its target price for the company's stock to $8. This adjustment indicates a continued positive outlook on the company's prospects despite a revised valuation.", "url": "https://www.moomoo.com/news/post/70857149/hc-wainwright-maintains-rein-therapeutics-rntxus-with-buy-rating-cuts", "source_name": "Moomoo", "published_at": "2026-06-02T07:10:16", "published_display": "02 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright cuts Rein Therapeutics stock price target on dilution By Investing.com", "summary": "H.C. Wainwright has reduced its price target for Rein Therapeutics (NASDAQ:RNTX) shares from $10.00 to $8.00, while maintaining a Buy rating. This adjustment reflects the dilution caused by a recent $57.5 million common-stock financing, which addressed the company's liquidity con", "url": "https://ca.investing.com/news/stock-market-news/hc-wainwright-cuts-rein-therapeutics-stock-price-target-on-dilution-93CH-4668527", "source_name": "Investing.com Canada", "published_at": "2026-06-01T11:39:36", "published_display": "01 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RNTX - Rein Therapeutics Inc Stock Price and Quote", "summary": "This article provides detailed stock information for Rein Therapeutics Inc (RNTX), including its last close price, financial overview, key performance indicators, and recent news announcements. It also lists insider transactions and historical analyst ratings, offering a comprehe", "url": "https://finviz.com/stock?t=RNTX", "source_name": "Finviz", "published_at": "2026-05-30T04:41:20", "published_display": "30 May 2026 04:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics director buys $49,560 in company stock", "summary": "Josef H. von Rickenbach, a director at Rein Therapeutics, Inc. (NASDAQ:RNTX), recently purchased $49,560 worth of company stock through open market transactions in late May 2026. This acquisition, totaling 47,060 shares, occurred as the company's shares gained nearly 8% over the ", "url": "https://www.investing.com/news/insider-trading-news/rein-therapeutics-director-buys-49560-in-company-stock-93CH-4715827", "source_name": "Investing.com", "published_at": "2026-05-29T00:40:09", "published_display": "29 May 2026 00:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rein-therapeutics-announces-closing-57-120000993.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T12:00:00+00:00", "published_display": "18 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Announces Closing Of $57.5 Million Underwritten Public Offering", "summary": "Rein Therapeutics has announced the closing of a $57.5 million underwritten public offering. The financial details of this offering were reported by Refinitiv. The article provides only this brief update without further elaboration.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN41V0SH:0-rein-therapeutics-announces-closing-of-57-5-million-underwritten-public-offering/", "source_name": "TradingView", "published_at": "2026-05-18T12:39:47", "published_display": "18 May 2026 12:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics closes $57.5 million stock offering", "summary": "Rein Therapeutics, Inc. (NASDAQ:RNTX) has successfully completed a $57.5 million public stock offering, selling 57.5 million shares at $1.00 each, including the underwriters' over-allotment option. The biopharmaceutical company plans to use the proceeds to fund its Phase 2 clinic", "url": "https://www.investing.com/news/company-news/rein-therapeutics-closes-575-million-stock-offering-93CH-4695599", "source_name": "Investing.com", "published_at": "2026-05-18T12:39:47", "published_display": "18 May 2026 12:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Announces Closing of $57.5 Million", "summary": "Rein Therapeutics announced the closing of a $57.5 million underwritten public offering, including the full exercise of the underwriters\u2019 over-allotment option. The gross proceeds will be used to fund its Phase 2 clinical trial of LTI-03 in idiopathic pulmonary fibrosis through c", "url": "https://www.globenewswire.com/news-release/2026/05/18/3296576/28652/en/rein-therapeutics-announces-closing-of-57-5-million-underwritten-public-offering-including-full-exercise-of-over-allotment-option.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T11:39:47", "published_display": "18 May 2026 11:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Rein Therapeutics raises $57.5M for lung fibrosis trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNUjlvSjg5MC1IYTVLYldnbVFTMkU2RXNRQlptRkkyLUFmV1pBemxWT0VvMFVBdnQ5aUkycGY0X0ZlSGo0RTRBeVBjdWVqS3oyQi1NRXo3WkluU09IRFhTTTBXcVpKSm1mM1h5cW1pS0Nrc0RKOENQa0lHUGhpSi1KRk1oUEV0VWVEc09JeldxQk9wVzNPa3poMHZRUldHYVphUlI1Si1TRWNrTndJTUllaXVzX2Y1bFR4U3Bv?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "RNTX Slides As Rein Therapeutics Stock Tests New Lows", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOQWFTRVVPZ0ZMYXRYUjVYRGtnNFM5QmxhdzRxSGQzcll6aWhXbFZTZGo2NVB2SnJuRHNTTVVhVThPUlFMVXI5TWZ3ZkhiaEpEQ1pQQnZqRDkyVk5CdkxEbm8zZWxWaUhrT1NnaE5MQ0xNY0hNUE5sV1o4WTVKclFxXw?oc=5", "source_name": "timothysykes.com", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Prices $50 Million Common Stock Offering; Shares Down Pre-Bell", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/rein-therapeutics-prices-50-million-101653985.html", "source_name": "MT Newswires", "published_at": "2026-05-01T10:16:53+00:00", "published_display": "01 May 2026 10:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics, Inc. Announces Pricing of $50 Million Public Offering of Common Stock | RNTX Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQbFdaTUNhbjRNZFFjMDBhU3hkWFdydzAta0NlNE1xTzFhZzFNU2g4ZE4zdVRBai05RHYxRmRKbUJ0Tk56WHkwU3B6VmxWamRDRnRRcm5XQ0J3a1RNNURtM2szSXdjMElNQmU3QU83U1RzRUM0eWJRd3ItNGFYTnY3VFlKYVQ0NDRYQTF4NDkxTzZjVXBka183bmZzY0t2Uk5TTDNmc0haZ09qZklTZDc1eHRQWS1XdHN6YTU2bjhUYjVfUFk?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxNcFF1QlFXV0RkdzBtSno0amZEQ1BfS1lZXzRmR3V6SWl3dkVVUFhVOVJaanNTekNzREwzSHpoTlVnWjNlWUw1bEJiQ0NVaWJ6MHN6QWJQblZNSzFmbnFlSjQ1bGZ6ck4zLUJZTUJWSFNTVDlpaTJqaU9CV21DTS1aZWtpeEZGX09DM1o4LS1TdjFiRXFXNE11Tk80WDRiRDBvNzFkRHdvOExQQi1HVVpRTjBNRk9UakhRY3NPdG5uX1FqWkpURXRxTlpINlk0eVVnSUwwSld0M0hGYUZOa1A2c3ZMYkFvZEpqcnVCSUpaTVFudElTN2tnVTln?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rein-therapeutics-provides-clinical-trial-120000795.html", "source_name": "GlobeNewswire", "published_at": "2026-04-29T12:00:00+00:00", "published_display": "29 Apr 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxNdzJ0NV9mRnVLX2RrWnhQWWZpSDlnNzBrSnM0ekFuTVVzRjVJdGZFWkRyNjNyZzdjRHE5TFJfNnNyR240U045M3c5SngxaGh0WlJrc1FGUEJiNFktSUhWNnRLZ3plVDB1U3pVaUQxZmc3Y29pQjZPQWpzZmJiRGlqcmJEUmcxRk0yaExoNGpfenB1amh3V1ZEZXJTR3B4cTc2QTRKa0lFRExyMjhFSDNKeTkwc29rX2xiV0R4WTh1YWQxZExfc2Z5cF9SbzZsY0t4cVJLekFkYmhoMTZrajdnWQ?oc=5", "source_name": "PR Newswire", "published_at": "2025-05-15T07:00:00+00:00", "published_display": "15 May 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxOalh4YTh4Y0VkUlpmU1ozMWtrN0lHeEMzeHNPTmNCQk9td0hFN2JneTdEbWhldmc1dW5tNE5kQ2RMMTNFZzBtcy1fVzVOUUVXclV3dlFmSkhSWjRSVEJvaDNGNTVlYUljYXVCTE4yTjd5LVF6U2c2UlEzZEV0TXVpalJiTTB0RVFXSTFjRjByV1RtSEpiRDROWUNxQzgtVldFZ25CNWtjajVHZG9MQWRaM2hWZFkyMnE1eGVMTGlfUFFQeDdDZV9sMkktMF90Z3FEZG9RZ1NYV0NDZWZ2ODdSb1FfbUtzTzU0cEJ1THVaZnBvdnZ1?oc=5", "source_name": "PR Newswire", "published_at": "2025-04-07T07:00:00+00:00", "published_display": "07 Apr 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics (RNTX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5lSENCY080THExMnphT0xNd2p4bmFRdTBaa2xVSVMtUThXakU3NURWb3NCS3gyMnhUMmJ1RVNUSGdObFpYbjRyU0JkRnNqM0lhcVZxVkRIWkE2dw?oc=5", "source_name": "MarketBeat", "published_at": "2025-02-08T14:18:43+00:00", "published_display": "08 Feb 2025 14:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RNTX Stock Price and Chart \u2014 NASDAQ:RNTX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE9Ta1pWV1VpVUx4M01GSVB3ZHJFR3RsZlhDVjRoZFhacElraC1EY3pndURMWXRZekRpOXNWTFdFSnpjQXJrNGJIOXFiaTRSN05PT0NheGYzS1FqWk1i?oc=5", "source_name": "TradingView", "published_at": "2025-01-13T20:07:11+00:00", "published_display": "13 Jan 2025 20:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics (RNTX) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTFBJblJ5bGJLX3pPeV93NmNLMTBKSVl3TldBRkxkNXlSekRrZFFIWHViUFVFSW5aR2hkRmlBUzFwR3BoV2NVZHRkS2xvQWNHUQ?oc=5", "source_name": "Stock Titan", "published_at": "2025-01-10T17:02:52+00:00", "published_display": "10 Jan 2025 17:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aileron Therapeutics Announces Rebranding to Rein Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQdUkwZDZnVk5aTlpVQVQ1VFpWZEpSOVFaaU1mN3BPcFlIZUhIMVRDaXZ5M01xb2ktMHp5akVWM1gyVlZIUkQtbk1JQlVWaTVvRmZVZVg2WHBFU3FuSWZReFFNR1VvS21XelZNQ0llS25qTHRSWlFsM3FrSDFDMFM2ODFOWXdSQm9ERTQtc3FjSzRHTi0wQS1kSUdjd1hPdWZoaXlhX2xKYTlZSjJIV1Vnci1CbzZpR0RhQkE?oc=5", "source_name": "PR Newswire", "published_at": "2025-01-10T08:00:00+00:00", "published_display": "10 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Rein Therapeutics (RNTX) Slips 1.78% as Stock Nears Key Support Level - McClellan Summation", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOa2ctSUk3aU02Mk9Zd0VrV1Fnc3E0WG9TV1dMV3lESS1ZV21uOHRteFdidUxEb0paR25GeHhHOG9ocDdFR09hdWFScUp5Tkc1NUszX29Xem5CQ2hZU0k0ejFpejBQY1l6eXhRd0lNY0ttR3J1YnY4alpoOHNIQWVFQWJFUFNnQlhtOWpySzlUTWJUMks4M3A4NVBKN3k4d3JvVk9QZzlTaW1TWVBvYUNqcE5rUkwyQQ?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-07-11T17:36:04+00:00", "published_display": "11 Jul 2026 17:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Rein Therapeutics, Inc. \u2013 NASDAQ:RNTX", "summary": "The article provides a title indicating \"Price to sales forward of Rein Therapeutics, Inc. \u2013 NASDAQ:RNTX\" and appears to be a financial data page from TradingView. It lists the company, its Nasdaq stock market ticker, and general financial and market information categories. Howev", "url": "https://www.tradingview.com/symbols/NASDAQ-RNTX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T15:40:22", "published_display": "10 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Rein Therapeutics, Inc. \u2013 NASDAQ:RNTX", "summary": "This article focuses on the enterprise value to revenue forward metric for Rein Therapeutics, Inc. (NASDAQ: RNTX). It appears to be a financial data point presented within a larger financial platform context, offering a snapshot of a specific valuation ratio for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-RNTX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T02:10:48", "published_display": "08 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Rein Therapeutics, Inc. \u2013 BOATS:RNTX", "summary": "The article discusses the \"Price to sales forward\" metric for Rein Therapeutics, Inc. (RNTX) on the Blue Ocean Alternative Trade System (BOATS) platform. This financial data is provided by TradingView, indicating that the market for RNTX was closed with no trades recorded at the ", "url": "https://www.tradingview.com/symbols/BOATS-RNTX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T20:11:11", "published_display": "07 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Rein Therapeutics, Inc. \u2013 BOATS:RNTX", "summary": "The article focuses on the \"Price to earnings forward\" metric for Rein Therapeutics, Inc. (RNTX), listed on the Blue Ocean Alternative Trade System (BOATS). It presents a financial data point for the pharmaceutical company but does not offer any specific figures or analysis withi", "url": "https://www.tradingview.com/symbols/BOATS-RNTX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T13:10:40", "published_display": "07 Jul 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Inc. (RNTX) Q1 2026 Earnings: Narrowed Loss Beats Estimates as Cash Management Improves", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxNUkI2U2NlajRKNlVvRDVVR09kVG52LUM3V3RwWTNHTmlnODZUQ09UeEhIYkpXa2ptQ0VZMGVZZkwyOWMzZ0NJaDhSM1ZvN2hIS0RfR09xZ3dfVm1zMXJaZ2lWS2xtZlVFaG8tNnRkLUxVa2psX3h1UDNjR0RQU2RmTnNUWUFwaXRIcm1YejB5a0c5ZmRlQ0ZJZ0VtUWxXaklLaEo4d0pyRnlXV0pIYlNFNlAydTF5cDJKakVBQlNUSmo1UXV1NTBBVXVDaHNsc0NkMFIzTDc0SlVWMUZG?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-06T23:40:08+00:00", "published_display": "06 Jul 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RNTX - Rein Therapeutics Inc Latest SEC Filings", "summary": "This article provides the latest SEC filing information for Rein Therapeutics Inc. (RNTX), detailing its financial performance, key metrics like market capitalization and sales, and stock performance data. It includes various financial ratios, insider and institutional ownership ", "url": "https://finviz.com/stock?t=RNTX&ta=1&p=w&ty=lf&page=3", "source_name": "Finviz", "published_at": "2026-07-05T07:40:51", "published_display": "05 Jul 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Inc.(NasdaqCM:RNTX) added to Russell Microcap Value Benchmark Index", "summary": "Rein Therapeutics Inc. (NasdaqCM:RNTX) has been added to the Russell Microcap Value Benchmark Index. The biotechnology company, specializing in orphan pulmonary and fibrosis indications, saw its stock increase by 1.94%, with its share price trading at $0.9900. This news follows s", "url": "https://www.marketscreener.com/news/rein-therapeutics-inc-nasdaqcm-rntx-added-to-russell-microcap-value-benchmark-index-ce7f5fdfd989f325", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T13:40:08", "published_display": "29 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RNTX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Rein Therapeutics, Inc. (RNTX) stock for 2027, based on analyst opinions. It highlights a maximum and minimum price target of $8.00 and includes financial data, recent stock performance, and answers frequently asked questions ", "url": "https://www.tradingview.com/symbols/NASDAQ-RNTX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T15:09:36", "published_display": "25 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics, Inc Actuals & Estimates (NASDAQ:RNTX)", "summary": "This article provides an overview of Rein Therapeutics, Inc. (NASDAQ: RNTX) stock, including its current price, performance, and analyst forecasts. It details financial actuals and estimates, market capitalization, earnings per share, revenue, and other key financial data. The ar", "url": "https://www.tradingview.com/symbols/NASDAQ-RNTX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T15:09:36", "published_display": "25 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics (RNTX) Surges 5.87% as Stock Tests Key Resistance at $0.97 - Sweep Order Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQLVVCRjh3QnhtQUkwTW1MNmViZW5sNVJzMWdfaUVIOUJ6MW55TF82cl9rU3Fvd1RxeUhFc2lMdWtxVXROUjlJX0haekpKaUtOWjFtMEtGdUo3bzRNNjBnamJWSE5VMHllWjBYaThIQmIxemRTVXdHTXdJWHZHeE9OZnhzd2wwcUhtc1ZaeTJKUVZzUzBXYTA3ZS1JaTBSb1l5c3NmQUVNZmoxbkk4OEJidzMxRkRORHE0Rkc0?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-20T07:00:00+00:00", "published_display": "20 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Inc (RNTX) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Rein Therapeutics Inc (RNTX), highlighting its current valuation score and P/E ratio. The company's valuation score is 8.52, ranking it 118 out of 389 in the Biotechnology & Medical Research industry, with a P/E ratio of -0.48. Key va", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rntx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T13:11:14", "published_display": "19 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Inc (RNTX) Institutional Confidence", "summary": "Rein Therapeutics Inc's institutional shareholding score is 3.00, placing it at 193 out of 389 in the Biotechnology & Medical Research industry. The company's latest institutional shareholding proportion is 16.21%, a decrease of 51.20% quarter-over-quarter. James Simons is identi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rntx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-19T13:11:14", "published_display": "19 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Inc (RNTX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "The article provides an analysis of Rein Therapeutics Inc.'s (RNTX) financial health, noting its weak financial status and low operating efficiency with a score of 5.52, ranking 350 out of 389 in its industry. Key financial metrics such as cash and cash equivalents, total assets,", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rntx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-19T13:11:14", "published_display": "19 Jun 2026 13:11", "sentiment": "negative", "sentiment_pct": 31, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Inc (RNTX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Rein Therapeutics Inc (RNTX) currently holds an earnings forecast score of 7.00, placing it 316th out of 389 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $8.00 for RNTX, with a high of $10.00 and a low of $6.00, suggesting an upsi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rntx/earnings", "source_name": "TradingKey", "published_at": "2026-06-19T00:10:27", "published_display": "19 Jun 2026 00:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Inc (RNTX) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Rein Therapeutics Inc. (RNTX), highlighting that no specific risk assessment score is available for the company. It details various risk metrics such as volatility, maximum drawdown, and liquidity, and notes the company's beta value of ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rntx/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-18T19:09:49", "published_display": "18 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Inc (RNTX) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Rein Therapeutics Inc (RNTX), highlighting its major shareholders and institutional holdings. Voss Capital LLC is the largest reported shareholder, with significant institutional investment activity tracked over several quarters. ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rntx/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T16:39:09", "published_display": "17 Jun 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Inc (RNTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Rein Therapeutics Inc (RNTX), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. As of June 18, 2026, RNTX's price momentum score is 6.70, with the stock trading betwee", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rntx/technical", "source_name": "TradingKey", "published_at": "2026-06-17T12:09:50", "published_display": "17 Jun 2026 12:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "All You Need to Know About Rein Therapeutics Inc. (RNTX) Rating Upgrade to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPMkhYYUpmRVZfUjFmWmZld3hTTEJNQlZTSnJTa19XbVZqTWNycTllOHVzRTlodXFSVXU5R19KVUFWVTFlYVBZUXNBXzFQZDVxYTNCcW1oNV9aV2tBVFlNbDdJa2lGcVRyZFUxOGRmbTl1X1hrN25ndU9RSFdNVDl1OEdLeXl3MGxmUHRFT2lnQzZVNW9GXzlhN0FpeUI?oc=5", "source_name": "Market source", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Inc (RNTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for Rein Therapeutics Inc (RNTX). It notes that relevant data regarding business segments, regional revenue, and profit contribution for various fiscal years have not yet been disclosed by the company. The only specific in", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rntx/revenue", "source_name": "TradingKey", "published_at": "2026-06-16T17:09:47", "published_display": "16 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics enrolls 16 patients in lung fibrosis trial By Investing.com", "summary": "Rein Therapeutics announced that its Phase 2 RENEW clinical trial for LTI-03, targeting idiopathic pulmonary fibrosis, has enrolled 16 patients and randomized the first participant in the UK. The trial, which will evaluate the safety, tolerability, and efficacy of LTI-03, plans t", "url": "https://ng.investing.com/news/stock-market-news/rein-therapeutics-enrolls-16-patients-in-lung-fibrosis-trial-93CH-2553861", "source_name": "Investing.com Nigeria", "published_at": "2026-06-16T07:09:31", "published_display": "16 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom", "summary": "Rein Therapeutics announced the expansion of its Phase 2 RENEW clinical trial for LTI-03, an idiopathic pulmonary fibrosis treatment, into the United Kingdom, where the first patient has been randomized. The company has enrolled 16 patients to date, with clinical trial sites acti", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rein-therapeutics-expands-phase-2-120000289.html", "source_name": "Market source", "published_at": "2026-06-12T11:11:02", "published_display": "12 Jun 2026 11:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics enrolls 16 patients in lung fibrosis trial", "summary": "Rein Therapeutics has announced that its Phase 2 RENEW clinical trial for LTI-03, targeting idiopathic pulmonary fibrosis, has enrolled 16 patients to date, with the first patient randomized in the UK. The trial expects to enroll about 120 patients across multiple countries to ev", "url": "https://www.investing.com/news/company-news/rein-therapeutics-enrolls-16-patients-in-lung-fibrosis-trial-93CH-4737322", "source_name": "Investing.com", "published_at": "2026-06-11T12:09:28", "published_display": "11 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IPF trial for LTI-03 adds first UK patient, expands to 3 countries", "summary": "Rein Therapeutics (NASDAQ: RNTX) announced that the first patient has been randomized in the United Kingdom for its Phase 2 RENEW clinical trial evaluating LTI-03 for idiopathic pulmonary fibrosis (IPF), bringing the total enrollment to 16 patients across the US, Australia, and t", "url": "https://www.stocktitan.net/news/RNTX/rein-therapeutics-expands-phase-2-renew-trial-into-united-8c9pe1fismfm.html", "source_name": "Stock Titan", "published_at": "2026-06-11T12:09:28", "published_display": "11 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics (NASDAQ: RNTX) 2026 proxy outlines share boost, director elections, pay", "summary": "Rein Therapeutics' 2026 proxy statement details key items for its virtual annual meeting on July 20, 2026, including the election of two Class III directors, a proposal to double authorized common shares from 100 million to 200 million, and the ratification of CBIZ CPAs P.C. as t", "url": "https://www.stocktitan.net/sec-filings/RNTX/def-14a-rein-therapeutics-inc-definitive-proxy-statement-f39226f80277.html", "source_name": "Stock Titan", "published_at": "2026-06-09T08:40:55", "published_display": "09 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Rein Therapeutics(RNTX.US) With Buy Rating, Cuts Target Price to $8", "summary": "H.C. Wainwright has reiterated its Buy rating for Rein Therapeutics (RNTX.US) but has lowered its target price for the company's stock to $8. This adjustment indicates a continued positive outlook on the company's prospects despite a revised valuation.", "url": "https://www.moomoo.com/news/post/70857149/hc-wainwright-maintains-rein-therapeutics-rntxus-with-buy-rating-cuts", "source_name": "Moomoo", "published_at": "2026-06-02T07:10:16", "published_display": "02 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright cuts Rein Therapeutics stock price target on dilution By Investing.com", "summary": "H.C. Wainwright has reduced its price target for Rein Therapeutics (NASDAQ:RNTX) shares from $10.00 to $8.00, while maintaining a Buy rating. This adjustment reflects the dilution caused by a recent $57.5 million common-stock financing, which addressed the company's liquidity con", "url": "https://ca.investing.com/news/stock-market-news/hc-wainwright-cuts-rein-therapeutics-stock-price-target-on-dilution-93CH-4668527", "source_name": "Investing.com Canada", "published_at": "2026-06-01T11:39:36", "published_display": "01 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RNTX - Rein Therapeutics Inc Stock Price and Quote", "summary": "This article provides detailed stock information for Rein Therapeutics Inc (RNTX), including its last close price, financial overview, key performance indicators, and recent news announcements. It also lists insider transactions and historical analyst ratings, offering a comprehe", "url": "https://finviz.com/stock?t=RNTX", "source_name": "Finviz", "published_at": "2026-05-30T04:41:20", "published_display": "30 May 2026 04:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics director buys $49,560 in company stock", "summary": "Josef H. von Rickenbach, a director at Rein Therapeutics, Inc. (NASDAQ:RNTX), recently purchased $49,560 worth of company stock through open market transactions in late May 2026. This acquisition, totaling 47,060 shares, occurred as the company's shares gained nearly 8% over the ", "url": "https://www.investing.com/news/insider-trading-news/rein-therapeutics-director-buys-49560-in-company-stock-93CH-4715827", "source_name": "Investing.com", "published_at": "2026-05-29T00:40:09", "published_display": "29 May 2026 00:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rein-therapeutics-announces-closing-57-120000993.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T12:00:00+00:00", "published_display": "18 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Announces Closing Of $57.5 Million Underwritten Public Offering", "summary": "Rein Therapeutics has announced the closing of a $57.5 million underwritten public offering. The financial details of this offering were reported by Refinitiv. The article provides only this brief update without further elaboration.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN41V0SH:0-rein-therapeutics-announces-closing-of-57-5-million-underwritten-public-offering/", "source_name": "TradingView", "published_at": "2026-05-18T12:39:47", "published_display": "18 May 2026 12:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics closes $57.5 million stock offering", "summary": "Rein Therapeutics, Inc. (NASDAQ:RNTX) has successfully completed a $57.5 million public stock offering, selling 57.5 million shares at $1.00 each, including the underwriters' over-allotment option. The biopharmaceutical company plans to use the proceeds to fund its Phase 2 clinic", "url": "https://www.investing.com/news/company-news/rein-therapeutics-closes-575-million-stock-offering-93CH-4695599", "source_name": "Investing.com", "published_at": "2026-05-18T12:39:47", "published_display": "18 May 2026 12:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Announces Closing of $57.5 Million", "summary": "Rein Therapeutics announced the closing of a $57.5 million underwritten public offering, including the full exercise of the underwriters\u2019 over-allotment option. The gross proceeds will be used to fund its Phase 2 clinical trial of LTI-03 in idiopathic pulmonary fibrosis through c", "url": "https://www.globenewswire.com/news-release/2026/05/18/3296576/28652/en/rein-therapeutics-announces-closing-of-57-5-million-underwritten-public-offering-including-full-exercise-of-over-allotment-option.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T11:39:47", "published_display": "18 May 2026 11:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Rein Therapeutics raises $57.5M for lung fibrosis trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNUjlvSjg5MC1IYTVLYldnbVFTMkU2RXNRQlptRkkyLUFmV1pBemxWT0VvMFVBdnQ5aUkycGY0X0ZlSGo0RTRBeVBjdWVqS3oyQi1NRXo3WkluU09IRFhTTTBXcVpKSm1mM1h5cW1pS0Nrc0RKOENQa0lHUGhpSi1KRk1oUEV0VWVEc09JeldxQk9wVzNPa3poMHZRUldHYVphUlI1Si1TRWNrTndJTUllaXVzX2Y1bFR4U3Bv?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RNTX Slides As Rein Therapeutics Stock Tests New Lows", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOQWFTRVVPZ0ZMYXRYUjVYRGtnNFM5QmxhdzRxSGQzcll6aWhXbFZTZGo2NVB2SnJuRHNTTVVhVThPUlFMVXI5TWZ3ZkhiaEpEQ1pQQnZqRDkyVk5CdkxEbm8zZWxWaUhrT1NnaE5MQ0xNY0hNUE5sV1o4WTVKclFxXw?oc=5", "source_name": "timothysykes.com", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Prices $50 Million Common Stock Offering; Shares Down Pre-Bell", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/rein-therapeutics-prices-50-million-101653985.html", "source_name": "MT Newswires", "published_at": "2026-05-01T10:16:53+00:00", "published_display": "01 May 2026 10:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics, Inc. Announces Pricing of $50 Million Public Offering of Common Stock | RNTX Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQbFdaTUNhbjRNZFFjMDBhU3hkWFdydzAta0NlNE1xTzFhZzFNU2g4ZE4zdVRBai05RHYxRmRKbUJ0Tk56WHkwU3B6VmxWamRDRnRRcm5XQ0J3a1RNNURtM2szSXdjMElNQmU3QU83U1RzRUM0eWJRd3ItNGFYTnY3VFlKYVQ0NDRYQTF4NDkxTzZjVXBka183bmZzY0t2Uk5TTDNmc0haZ09qZklTZDc1eHRQWS1XdHN6YTU2bjhUYjVfUFk?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxNcFF1QlFXV0RkdzBtSno0amZEQ1BfS1lZXzRmR3V6SWl3dkVVUFhVOVJaanNTekNzREwzSHpoTlVnWjNlWUw1bEJiQ0NVaWJ6MHN6QWJQblZNSzFmbnFlSjQ1bGZ6ck4zLUJZTUJWSFNTVDlpaTJqaU9CV21DTS1aZWtpeEZGX09DM1o4LS1TdjFiRXFXNE11Tk80WDRiRDBvNzFkRHdvOExQQi1HVVpRTjBNRk9UakhRY3NPdG5uX1FqWkpURXRxTlpINlk0eVVnSUwwSld0M0hGYUZOa1A2c3ZMYkFvZEpqcnVCSUpaTVFudElTN2tnVTln?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rein-therapeutics-provides-clinical-trial-120000795.html", "source_name": "GlobeNewswire", "published_at": "2026-04-29T12:00:00+00:00", "published_display": "29 Apr 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxNdzJ0NV9mRnVLX2RrWnhQWWZpSDlnNzBrSnM0ekFuTVVzRjVJdGZFWkRyNjNyZzdjRHE5TFJfNnNyR240U045M3c5SngxaGh0WlJrc1FGUEJiNFktSUhWNnRLZ3plVDB1U3pVaUQxZmc3Y29pQjZPQWpzZmJiRGlqcmJEUmcxRk0yaExoNGpfenB1amh3V1ZEZXJTR3B4cTc2QTRKa0lFRExyMjhFSDNKeTkwc29rX2xiV0R4WTh1YWQxZExfc2Z5cF9SbzZsY0t4cVJLekFkYmhoMTZrajdnWQ?oc=5", "source_name": "PR Newswire", "published_at": "2025-05-15T07:00:00+00:00", "published_display": "15 May 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxOalh4YTh4Y0VkUlpmU1ozMWtrN0lHeEMzeHNPTmNCQk9td0hFN2JneTdEbWhldmc1dW5tNE5kQ2RMMTNFZzBtcy1fVzVOUUVXclV3dlFmSkhSWjRSVEJvaDNGNTVlYUljYXVCTE4yTjd5LVF6U2c2UlEzZEV0TXVpalJiTTB0RVFXSTFjRjByV1RtSEpiRDROWUNxQzgtVldFZ25CNWtjajVHZG9MQWRaM2hWZFkyMnE1eGVMTGlfUFFQeDdDZV9sMkktMF90Z3FEZG9RZ1NYV0NDZWZ2ODdSb1FfbUtzTzU0cEJ1THVaZnBvdnZ1?oc=5", "source_name": "PR Newswire", "published_at": "2025-04-07T07:00:00+00:00", "published_display": "07 Apr 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics (RNTX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5lSENCY080THExMnphT0xNd2p4bmFRdTBaa2xVSVMtUThXakU3NURWb3NCS3gyMnhUMmJ1RVNUSGdObFpYbjRyU0JkRnNqM0lhcVZxVkRIWkE2dw?oc=5", "source_name": "MarketBeat", "published_at": "2025-02-08T14:18:43+00:00", "published_display": "08 Feb 2025 14:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RNTX Stock Price and Chart \u2014 NASDAQ:RNTX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE9Ta1pWV1VpVUx4M01GSVB3ZHJFR3RsZlhDVjRoZFhacElraC1EY3pndURMWXRZekRpOXNWTFdFSnpjQXJrNGJIOXFiaTRSN05PT0NheGYzS1FqWk1i?oc=5", "source_name": "TradingView", "published_at": "2025-01-13T20:07:11+00:00", "published_display": "13 Jan 2025 20:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rein Therapeutics (RNTX) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTFBJblJ5bGJLX3pPeV93NmNLMTBKSVl3TldBRkxkNXlSekRrZFFIWHViUFVFSW5aR2hkRmlBUzFwR3BoV2NVZHRkS2xvQWNHUQ?oc=5", "source_name": "Stock Titan", "published_at": "2025-01-10T17:02:52+00:00", "published_display": "10 Jan 2025 17:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aileron Therapeutics Announces Rebranding to Rein Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQdUkwZDZnVk5aTlpVQVQ1VFpWZEpSOVFaaU1mN3BPcFlIZUhIMVRDaXZ5M01xb2ktMHp5akVWM1gyVlZIUkQtbk1JQlVWaTVvRmZVZVg2WHBFU3FuSWZReFFNR1VvS21XelZNQ0llS25qTHRSWlFsM3FrSDFDMFM2ODFOWXdSQm9ERTQtc3FjSzRHTi0wQS1kSUdjd1hPdWZoaXlhX2xKYTlZSjJIV1Vnci1CbzZpR0RhQkE?oc=5", "source_name": "PR Newswire", "published_at": "2025-01-10T08:00:00+00:00", "published_display": "10 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 94, "total_relevant": 53, "sentiment_summary": {"positive": 13, "negative": 3, "neutral": 37, "score": 54, "total": 53, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 15.4, "count": 28}, {"event": "earnings", "label": "Earnings", "weight": 7.7, "count": 16}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 13, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 0.98, "latest_week": "2026-07-10", "one_week_move": -1.2, "four_week_move": 2.3, "twelve_week_move": -44.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.69403, "market_dynamics_buy_signal": false, "relative_strength": -33.561915, "fair_value_gap": -56.8, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 47.3936, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.2% over one week, +2.3% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 62, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 9}, {"label": "TradingKey", "count": 8}, {"label": "Market source", "count": 7}, {"label": "Stock Titan", "count": 4}, {"label": "GlobeNewswire", "count": 4}, {"label": "Investing.com", "count": 3}, {"label": "PR Newswire", "count": 3}, {"label": "Donan\u0131mHaber", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 45}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 28}, {"label": "Earnings", "count": 16}, {"label": "Analyst action", "count": 5}, {"label": "Balance sheet", "count": 2}, {"label": "Guidance", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "45", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-1.2% over one week, +2.3% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Rein Therapeutics (RNTX) Slips 1.78% as Stock Nears Key Support Level - McClellan Summation"}], "updated_at": "2026-07-16T00:21:15.466162+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}